Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT–YB1–MDR1 Signaling Pathway
Dongliang Mo(Beijing Institute of Genomics), Yongliang Zhao(State Grid Corporation of China (China)), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Adayabalam S. Balajee(Oak Ridge Associated Universities), Hongbo Fang(Beijing Institute of Genomics), Arvind Arora(Himalayan Institute Hospital Trust), Meng Wu(University of Alberta), Mohammed A. Aleskandarany(Nottingham University Hospitals NHS Trust), Kaifeng Niu(Beijing Institute of Genomics), Shiyou Li(Stephen F. Austin State University), Jing Liu(Central South University), Tienian Zhu(Hebei Medical University), Zhenfen Chi(Beijing Institute of Genomics), Dileep N. Lobo(Nottingham University Hospitals NHS Trust)
Cited by 105
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder
|Neuroscience & Biobehavioral Reviews|2021|1.4k
The Attractive Female Body Weight and Female Body Dissatisfaction in 26 Countries Across 10 World Regions: Results of the International Body Project I
|Personality and Social Psychology Bulletin|2010|718
Guidelines for Perioperative Care in Bariatric Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations
|World Journal of Surgery|2016|607